Methoxypoly(ethylene glycol)-conjugated carboxypeptidase A for solid tumor targeting: Part II: Pharmacokinetics and biodistribution in normal and tumor-bearing rodents

Journal of Controlled Release

Volumn 104, Issue 1, 2005, Pages 155-166

  Ton, Giangthy N ^a   Weichert, Jamey P ^a   Longino, Marc A ^a   Fine, Jason P ^b   Kwon, Glen S ^c  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Computed tomography (CT); Enzyme prodrug therapy; Pretargeting; Tumor to blood ratio; Scintigraphy

Indexed keywords

ANTIBODIES; BLOOD; POLYETHYLENE GLYCOLS; REACTION KINETICS; TUMORS;

CARBOXYPEPTIDASE A (CPA); RATS; SOLID TUMORS; TUMOR LOCALIZATION;

ENZYMES;

CARBOXYPEPTIDASE A; MACROGOL DERIVATIVE; METHOXYPOLY(ETHYLENE GLYCOL); UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RETENTION; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; GAMMA SCINTIGRAPHY; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; RAT; SOLID TUMOR; TISSUE DISTRIBUTION; TUMOR LOCALIZATION;

EID: 18144379158     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.01.015     Document Type: Article

References (24)

1. R.F. Sherwood Advanced drug delivery reviews: enzyme prodrug therapy Adv. Drug Deliv. Rev. 22 1996 269 288
2. P.D. Senter, and C.J. Springer Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates Adv. Drug Deliv. Rev. 53 2001 247 264
3. R. Satchi, T.A. Connors, and R. Duncan PDEPT: polymer-directed enzyme prodrug therapy: 1. HPMA copolymer-cathepsin B and PK1 as a model combination Br. J. Cancer 85 7 2001 1070 1076
4. R. Satchi-Fainaro, H. Hailu, J.W. Davies, C. Summerford, and R. Duncan PDEPT: polymer-directed enzyme prodrug therapy: 2. HPMA copolymer-β- lactamase and HPMA copolymer-C-DOx as a model combination Bioconjug. Chem. 14 2003 797 804
5. R.K. Jain Delivery of molecular and cellular medicine to solid tumors Adv. Drug Deliv. Rev. 26 1997 71 90
6. H. Hashizume, P. Baluk, S. Morikawa, J.W. McLean, G. Thurston, S. Roberge, R.K. Jain, and D.M. McDonald Openings between defective endothelial cells explain tumor vessel leakiness Am. J. Pathol. 156 4 2000 1363 1380
7. R.J. Francis, S.K. Sharma, C. Springer, A.J. Green, L.D. Hope-Stone, L. Sena, J. Martin, K.L. Adamson, A. Robbins, L. Gumbrell, D. O'Malley, E. Tsiompanou, H. Shahbakhti, S. Webley, D. Hochhauser, A.J. Hilson, D. Blakey, and R.H.J. Begent A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumors Br. J. Cancer 87 2002 600 607
8. P.M. Deckert, C. Renner, L.S. Cohen, A. Jungbluth, G. Ritter, J.R. Bertino, L.J. Old, and S. Welt A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy Br. J. Cancer 88 2003 937 939
9. S.K. Sharma, K.D. Bagshawe, P.J. Burke, J.A. Boden, G.T. Rogers, C.J. Springer, R.G. Melton, and R.F. Sherwood Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy Cancer 73 3 Suppl. 1994 1114 1120
10. T.L. Cheng, P.Y. Wu, M.F. Wu, J.W. Chern, and S.R. Roffler Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM Bioconjug. Chem. 10 1999 520 528
11. M.S. Hershfield PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years Clin. Immunol. Immunopathol. 76 3 Pt 2 1995 S228 S232
12. L.M. Holle Pegaspargase: an alternative Ann. Pharmacother. 3 1997 616 624
13. P. Bailon, A. Palleroni, C.A. Schaffer, C.L. Spence, W.-J. Fung, J.E. Porter, G.K. Ehrlich, W. Pan, Z.-X. Xu, M.W. Modi, A. Farid, and W. Berthold Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C Bioconjug. Chem. 12 2001 195 202
14. K.D. Bagshawe, P.J. Burke, R.J. Knox, R.G. Melton, and S.K. Sharma Targeting enzymes to cancers-new developments Expert Opin. Investig. Drugs 8 2 1999 161 172
15. G.N. Ton, J.P. Fine, G.S. Kwon, Poly(ethylene glycol)-conjugated carboxypeptidase A: Part I. Synthesis and characterization evaluation, J. Control. Release (in press) (Revised Jan 2004).
16. A.N. Carter F.M. Ausubel R. Brent R.E. Kingston D.D. Moore J.G. Seidman J.A. Smith K. Struhl Short Protocols in Molecular Biology 1999 John Wiley & Son Inc
17. J.L. Gabrielsson, and D.L. Weiner Methodology for pharmacokinetic/ pharmacodynamic data analysis Pharm. Sci. Technol. Today 2 1999 244 252
18. R. Chizzonite, T. Truitt, F.J. Podlaski, A.G. Wolitzky, P.M. Quinn, P. Nunes, A.S. Stern, and M.K. Gately IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts J. Immunol. 147 5 1991 1548 1556
19. M.J. Knauf, D.P. Bell, P. Hirtzer, Z.P. Luo, J.D. Young, and N.V. Katre Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers J. Biol. Chem. 263 29 1988 15064 15070
20. C. Kronman, B.B. Velan, D. Marcus, A. Ordentlich, S. Reuveny, and A. Shafferman Involvement of oligomerization, N-glycosylation and sialylation in the clearance of cholinesterases from the circulation Biochem. J. 311 1995 959 967
21. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer therapy: mechanism of tumoritropic accumulation of proteins and the antitumor agents SMANCS Cancer Res. 46 1986 6387 6392
22. H. Maeda SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy Adv. Drug Deliv. Rev. 46 2001 169 185
23. L.A. Wolfe, R.J. Mullin, T.A. Blumenkopf, M. Cory, J.F. Miller, B.R. Keith, J. Humphreys, and G.K. Smith Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW 1843 Bioconjug. Chem. 10 1999 38 48
24. Y. Murakami, Y. Tabata, and Y. Ikada Tumor accumulation of poly(ethylene glycol) with different molecular weights after intravenous injection Drug Deliv. 4 1997 23 31